Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)

Frank C. Detterbeck, Michael A. Jantz, Michael Wallace, Johan Vansteenkiste, Gerard A. Silvestri

Research output: Contribution to journalArticle

548 Citations (Scopus)

Abstract

Background: The treatment of non-small cell lung cancer (NSCLC) is determined by accurate definition of the stage. If there are no distant metastases, the status of the mediastinal lymph nodes is critical. Although imaging studies can provide some guidance, in many situations invasive staging is necessary. Many different complementary techniques are available. Methods: The current guidelines and medical literature that are applicable to this issue were identified by computerized search and were evaluated using standardized methods. Recommendations were framed using the approach described by the Health and Science Policy Committee of the American College of Chest Physicians. Results: Performance characteristics of invasive staging interventions are defined. However, a direct comparison of these results is not warranted because the patients selected for these procedures have been different. It is crucial to define patient groups, and to define the need for an invasive test and selection of the best test based on this. Conclusions: In patients with extensive mediastinal infiltration, invasive staging is not needed. In patients with discrete node enlargement, staging by CT or positron emission tomography (PET) scanning is not sufficiently accurate. The sensitivity of various techniques is similar in this setting, although the false-negative (FN) rate of needle techniques is higher than that for mediastinoscopy. In patients with a stage II or a central tumor, invasive staging of the mediastinal nodes is necessary. Mediastinoscopy is generally preferable because of the higher FN rates of needle techniques in the setting of normal-sized lymph nodes. Patients with a peripheral clinical stage I NSCLC do not usually need invasive confirmation of mediastinal nodes unless a PET scan finding is positive in the nodes. The staging of patients with left upper lobe tumors should include an assessment of the aortopulmonary window lymph nodes.

Original languageEnglish (US)
JournalChest
Volume132
Issue number3 SUPPL.
DOIs
StatePublished - Sep 2007

Fingerprint

Evidence-Based Practice
Practice Guidelines
Lung Neoplasms
Mediastinoscopy
Lymph Nodes
Non-Small Cell Lung Carcinoma
Positron-Emission Tomography
Needles
Neoplasm Staging
Health Policy
Guidelines
Neoplasm Metastasis
Neoplasms

Keywords

  • Anterior mediastinotomy
  • Bronchoscopy
  • Chamberlain procedure
  • Clinical staging
  • Endobronchial ultrasound
  • Esophageal ultrasound
  • Mediastinal lymph nodes
  • Mediastinoscopy
  • N2
  • N3
  • Pathologic staging
  • Staging
  • Transbronchial needle aspiration

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Detterbeck, F. C., Jantz, M. A., Wallace, M., Vansteenkiste, J., & Silvestri, G. A. (2007). Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 132(3 SUPPL.). https://doi.org/10.1378/chest.07-1362

Invasive mediastinal staging of lung cancer : ACCP evidence-based clinical practice guidelines (2nd edition). / Detterbeck, Frank C.; Jantz, Michael A.; Wallace, Michael; Vansteenkiste, Johan; Silvestri, Gerard A.

In: Chest, Vol. 132, No. 3 SUPPL., 09.2007.

Research output: Contribution to journalArticle

Detterbeck, FC, Jantz, MA, Wallace, M, Vansteenkiste, J & Silvestri, GA 2007, 'Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)', Chest, vol. 132, no. 3 SUPPL.. https://doi.org/10.1378/chest.07-1362
Detterbeck, Frank C. ; Jantz, Michael A. ; Wallace, Michael ; Vansteenkiste, Johan ; Silvestri, Gerard A. / Invasive mediastinal staging of lung cancer : ACCP evidence-based clinical practice guidelines (2nd edition). In: Chest. 2007 ; Vol. 132, No. 3 SUPPL.
@article{4808402d12e1460abd7ca1b6ee55b353,
title = "Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)",
abstract = "Background: The treatment of non-small cell lung cancer (NSCLC) is determined by accurate definition of the stage. If there are no distant metastases, the status of the mediastinal lymph nodes is critical. Although imaging studies can provide some guidance, in many situations invasive staging is necessary. Many different complementary techniques are available. Methods: The current guidelines and medical literature that are applicable to this issue were identified by computerized search and were evaluated using standardized methods. Recommendations were framed using the approach described by the Health and Science Policy Committee of the American College of Chest Physicians. Results: Performance characteristics of invasive staging interventions are defined. However, a direct comparison of these results is not warranted because the patients selected for these procedures have been different. It is crucial to define patient groups, and to define the need for an invasive test and selection of the best test based on this. Conclusions: In patients with extensive mediastinal infiltration, invasive staging is not needed. In patients with discrete node enlargement, staging by CT or positron emission tomography (PET) scanning is not sufficiently accurate. The sensitivity of various techniques is similar in this setting, although the false-negative (FN) rate of needle techniques is higher than that for mediastinoscopy. In patients with a stage II or a central tumor, invasive staging of the mediastinal nodes is necessary. Mediastinoscopy is generally preferable because of the higher FN rates of needle techniques in the setting of normal-sized lymph nodes. Patients with a peripheral clinical stage I NSCLC do not usually need invasive confirmation of mediastinal nodes unless a PET scan finding is positive in the nodes. The staging of patients with left upper lobe tumors should include an assessment of the aortopulmonary window lymph nodes.",
keywords = "Anterior mediastinotomy, Bronchoscopy, Chamberlain procedure, Clinical staging, Endobronchial ultrasound, Esophageal ultrasound, Mediastinal lymph nodes, Mediastinoscopy, N2, N3, Pathologic staging, Staging, Transbronchial needle aspiration",
author = "Detterbeck, {Frank C.} and Jantz, {Michael A.} and Michael Wallace and Johan Vansteenkiste and Silvestri, {Gerard A.}",
year = "2007",
month = "9",
doi = "10.1378/chest.07-1362",
language = "English (US)",
volume = "132",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "3 SUPPL.",

}

TY - JOUR

T1 - Invasive mediastinal staging of lung cancer

T2 - ACCP evidence-based clinical practice guidelines (2nd edition)

AU - Detterbeck, Frank C.

AU - Jantz, Michael A.

AU - Wallace, Michael

AU - Vansteenkiste, Johan

AU - Silvestri, Gerard A.

PY - 2007/9

Y1 - 2007/9

N2 - Background: The treatment of non-small cell lung cancer (NSCLC) is determined by accurate definition of the stage. If there are no distant metastases, the status of the mediastinal lymph nodes is critical. Although imaging studies can provide some guidance, in many situations invasive staging is necessary. Many different complementary techniques are available. Methods: The current guidelines and medical literature that are applicable to this issue were identified by computerized search and were evaluated using standardized methods. Recommendations were framed using the approach described by the Health and Science Policy Committee of the American College of Chest Physicians. Results: Performance characteristics of invasive staging interventions are defined. However, a direct comparison of these results is not warranted because the patients selected for these procedures have been different. It is crucial to define patient groups, and to define the need for an invasive test and selection of the best test based on this. Conclusions: In patients with extensive mediastinal infiltration, invasive staging is not needed. In patients with discrete node enlargement, staging by CT or positron emission tomography (PET) scanning is not sufficiently accurate. The sensitivity of various techniques is similar in this setting, although the false-negative (FN) rate of needle techniques is higher than that for mediastinoscopy. In patients with a stage II or a central tumor, invasive staging of the mediastinal nodes is necessary. Mediastinoscopy is generally preferable because of the higher FN rates of needle techniques in the setting of normal-sized lymph nodes. Patients with a peripheral clinical stage I NSCLC do not usually need invasive confirmation of mediastinal nodes unless a PET scan finding is positive in the nodes. The staging of patients with left upper lobe tumors should include an assessment of the aortopulmonary window lymph nodes.

AB - Background: The treatment of non-small cell lung cancer (NSCLC) is determined by accurate definition of the stage. If there are no distant metastases, the status of the mediastinal lymph nodes is critical. Although imaging studies can provide some guidance, in many situations invasive staging is necessary. Many different complementary techniques are available. Methods: The current guidelines and medical literature that are applicable to this issue were identified by computerized search and were evaluated using standardized methods. Recommendations were framed using the approach described by the Health and Science Policy Committee of the American College of Chest Physicians. Results: Performance characteristics of invasive staging interventions are defined. However, a direct comparison of these results is not warranted because the patients selected for these procedures have been different. It is crucial to define patient groups, and to define the need for an invasive test and selection of the best test based on this. Conclusions: In patients with extensive mediastinal infiltration, invasive staging is not needed. In patients with discrete node enlargement, staging by CT or positron emission tomography (PET) scanning is not sufficiently accurate. The sensitivity of various techniques is similar in this setting, although the false-negative (FN) rate of needle techniques is higher than that for mediastinoscopy. In patients with a stage II or a central tumor, invasive staging of the mediastinal nodes is necessary. Mediastinoscopy is generally preferable because of the higher FN rates of needle techniques in the setting of normal-sized lymph nodes. Patients with a peripheral clinical stage I NSCLC do not usually need invasive confirmation of mediastinal nodes unless a PET scan finding is positive in the nodes. The staging of patients with left upper lobe tumors should include an assessment of the aortopulmonary window lymph nodes.

KW - Anterior mediastinotomy

KW - Bronchoscopy

KW - Chamberlain procedure

KW - Clinical staging

KW - Endobronchial ultrasound

KW - Esophageal ultrasound

KW - Mediastinal lymph nodes

KW - Mediastinoscopy

KW - N2

KW - N3

KW - Pathologic staging

KW - Staging

KW - Transbronchial needle aspiration

UR - http://www.scopus.com/inward/record.url?scp=34848823803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848823803&partnerID=8YFLogxK

U2 - 10.1378/chest.07-1362

DO - 10.1378/chest.07-1362

M3 - Article

C2 - 17873169

AN - SCOPUS:34848823803

VL - 132

JO - Chest

JF - Chest

SN - 0012-3692

IS - 3 SUPPL.

ER -